Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexmedetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexmedetomidine SCHEMBL14080529 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL28871763 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL204843 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL3911371 | 1.00 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL14861666 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL26432 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL29431568 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL18497244 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Dexmedetomidine SCHEMBL119382 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| Medetomidine SCHEMBL787913 | 0.98 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121588023-B | Soluble microneedle | ZHONGKE WEIZHEN (BEIJING) TECHNOLOGY Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260137633-A1 | DEXMEDETOMIDINE MICRONEEDLE PATCH, PREPARATION METHOD AND APPLICATION THEREOF | GUANGZHOU NOVAKEN PHARM CO LTD (CN) | 2026-05-21 | — | — | US | claimed |
| CN-122005608-A | Anesthetic and preparation method thereof | 柳州市工人医院 | 2026-05-12 | — | — | CN | claimed |
| EP-4731214-A1 | DEXMEDETOMIDINE TREATMENT REGIMENS | BioXcel Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20250325521-A1 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | BIOXCEL THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | claimed |
| US-20250288558-A1 | THERAPEUTIC FOR SPINAL CORD INJURY TO INDUCE HYPOTHERMIA | THE TRUSTEES OF INDIANA UNIVERSITY | 2025-09-18 | — | — | US | claimed |
| US-20250235554-A1 | METHODS FOR IMPROVING ADENO-ASSOCIATED VIRUS (AAV) DELIVERY | NOVARTIS AG (CH) | 2025-07-24 | — | — | US | claimed |
| US-20250228833-A1 | METHODS AND COMPOSITIONS FOR TREATING AGITATION | BIOXCEL THERAPEUTICS, INC. | 2025-07-17 | — | — | US | claimed |
| CN-120130466-A | Cornea endothelial cell protecting liquid for reducing metabolism of cornea endothelial cells | 山东第一医科大学附属眼科医院(山东省眼科医院) | 2025-06-13 | — | — | CN | claimed |
| CN-119954620-A | Dexmedetomidine hydrochloride new impurity and preparation method thereof | 湖北丽益医药科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-103694175-A | New method for preparing dexmedetomidine hydrochloride | BEIJING HUAXI LIANHE TECHNOLOGY DEV CO LTD | 2014-04-02 | — | — | CN | claimed |
| CN-103284945-A | Preparation method of pre-filled dexmedetomidine hydrochloride injection | SICHUAN BIOKIN PHARMACEUTICAL CO LTD | 2013-09-11 | — | — | CN | claimed |
| US-20130072532-A1 | TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | RECRO PHARMA, INC. (US) | 2013-03-21 | — | — | US | claimed |
| EP-2521544-A2 | TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | Recro Pharma, Inc. (US) | 2012-11-14 | — | — | EP | claimed |
| EP-2429521-A2 | SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | Recro Pharma, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2011085162-A2 | TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | RECRO PHARMA, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| WO-2010132882-A2 | SUBLINGUAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | RECRO PHARMA, INC. (US) | 2010-11-18 | — | — | WO | claimed |
| CN-101805294-A | Preparation of dexmedetomidine hydrochloride key intermediate | HUAXIPHARM CO LTD | 2010-08-18 | — | — | CN | claimed |
| US-20050101621-A1 | Method for rapid detoxification of addiction | DETOX SOLUTIONS LLC | 2005-05-12 | — | — | US | claimed |
| EP-0019694-B1 | PROCESSOR CONTROLLED PRINTING DEVICE AND OPERATION THEREOF | International Business Machines Corporation (US) | 1986-06-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072532-A1 | TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF | ADRA2C, ADRA2A, ADRB2 | ADRA2A 2/4885ADRA2B 4/4885ADRA2C 1/4885 |
| US-20260137633-A1 | DEXMEDETOMIDINE MICRONEEDLE PATCH, PREPARATION METHOD AND APPLICATION THEREOF | CD69, IDO2, IDO1 | ADRA2A 52/4885ADRA2B 119/4885ADRA2C 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.